J Treleaven - Concepedia

Author

J Treleaven

Royal Marsden Hospital

Also Known As

J G Treleaven, J Treleaven, J. TRELEAVEN, J. Treleaven, J.G. Treleaven, JENNIFER TRELEAVEN, Jennifer Treleaven

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

Royal Marsden Hospital Royal Marsden NHS Foundation Trust Institute of Cancer Research Northwestern University University of Ulster

About

J Treleaven is an author at Royal Marsden Hospital specializing in medicine, hematology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	26	1.6K
2	Health Sciences	6	6	548
3	Blood Transplantation	5	5	519
4	Social Sciences	1	1	19
5	Cell Biology	1	1	25

J Treleaven

Publications

Citations

H-Index

Page 1

	Year	Citations
Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial R Powles, Jayesh Mehta, Samar Kulkarni, The Lancet TransplantationMarrow TransplantationMedicineRandomised TrialStem Cell Transplantation	2000	355
HIGH-DOSE INTRAVENOUS IgG IN ADULTS WITH AUTOIMMUNE THROMBOCYTOPENIA Adrian C. Newland, J Treleaven, R. M. Minchinton, The Lancet ThrombopoiesisThrombosisAutoimmune DiseaseHematologyImmunology	1983	249
A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 × 106 CD34+ cells/kg be considered the minimum threshold? Seema Singhal, R Powles, J Treleaven, Bone Marrow Transplantation Hematological MalignancyTransplantationCd34+ Cells/kgStem Cell TransplantationImmunology	2000	110
Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma Seema Singhal, R Powles, Bhawna Sirohi, Bone Marrow Transplantation Hematological MalignancySurvival BenefitMedicineImmunologyMetronomic Chemotherapy	2002	83
Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease Fiona L. Dignan, Dorothy M. Gujral, Mark Ethell, Bone Marrow Transplantation TransplantationMarrow TransplantationProphylactic DefibrotideStem Cell TransplantationImmunology	2007	81
Outcome of acute leukemia relapsing after bone marrow transplantation: utility of second transplants and adoptive immunotherapy Jayesh Mehta, R Powles, J Treleaven, Bone Marrow Transplantation Radiation OncologyTransplantationMarrow TransplantationStem Cell TransplantationImmunology	1997	80
Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow. van Rhee F, D I Marks, Richard Szydlo, PubMed	1995	74
Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies Jayesh Mehta, S. M. Kelsey, Patrick Chu, Bone Marrow Transplantation Antifungal AgentAntifungal AgentsMalignant Blood DisorderHematologyImmunology	1997	68
Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment R Powles, Noopur Raje, S Milan, Bone Marrow Transplantation Unselected Myeloma PatientsPrognostic EvaluationHematological MalignancyOncologyHematology	1997	65
A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C‐VAMP) as induction treatment followed by autografting in previously untreated myeloma Noopur Raje, R Powles, Samar Kulkarni, British Journal of Haematology	1997	62

Page 1